Insider Selling: Phibro Animal Health (NASDAQ:PAHC) CEO Sells $219,562.72 in Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 4,528 shares of the stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $48.49, for a total value of $219,562.72. Following the sale, the chief executive officer directly owned 56,152 shares of the company’s stock, valued at approximately $2,722,810.48. This represents a 7.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jack Bendheim also recently made the following trade(s):

• On Tuesday, May 5th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $55.80, for a total value of $392,832.00.
• On Thursday, April 30th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $52.76, for a total value of $371,430.40.
• On Tuesday, April 28th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $55.91, for a total value of $393,606.40.
• On Wednesday, April 22nd, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $54.29, for a total value of $382,201.60.
• On Thursday, April 16th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $54.64, for a total value of $384,665.60.
• On Tuesday, April 14th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $59.08, for a total value of $415,923.20.
• On Thursday, March 19th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.52, for a total value of $369,740.80.
• On Wednesday, March 18th, Jack Bendheim sold 10,560 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.68, for a total value of $556,300.80.
• On Tuesday, March 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.66, for a total value of $272,764.80.
• On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.91, for a total value of $258,244.80.

Phibro Animal Health Price Performance

Phibro Animal Health stock opened at $40.00 on Friday. Phibro Animal Health Corporation has a one year low of $22.16 and a one year high of $60.08. The company has a debt-to-equity ratio of 1.97, a quick ratio of 1.22 and a current ratio of 3.17. The business has a fifty day moving average of $53.90 and a two-hundred day moving average of $46.51. The company has a market cap of $1.62 billion, a P/E ratio of 17.17, a price-to-earnings-growth ratio of 0.61 and a beta of 0.61.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, May 6th. The company reported $0.76 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.04. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.The company had revenue of $383.54 million during the quarter, compared to the consensus estimate of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. As a group, analysts predict that Phibro Animal Health Corporation will post 3.06 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 24th. Shareholders of record on Wednesday, June 3rd will be issued a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, June 3rd. This represents a $0.48 dividend on an annualized basis and a yield of 1.2%. Phibro Animal Health’s dividend payout ratio (DPR) is 20.60%.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Wall Street Zen downgraded Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday. Weiss Ratings downgraded Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday. Citigroup initiated coverage on Phibro Animal Health in a research note on Wednesday, April 15th. They set a “neutral” rating and a $62.00 price target for the company. Morgan Stanley set a $49.00 price target on Phibro Animal Health in a research note on Friday, February 6th. Finally, Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 11th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $42.40.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PAHC. 1620 Investment Advisors Inc. raised its stake in shares of Phibro Animal Health by 77.4% during the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock worth $25,000 after buying an additional 295 shares during the last quarter. Farther Finance Advisors LLC raised its stake in shares of Phibro Animal Health by 113.2% during the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after buying an additional 386 shares during the last quarter. KBC Group NV purchased a new stake in Phibro Animal Health during the 1st quarter worth about $29,000. Rothschild Investment LLC increased its position in Phibro Animal Health by 2,500.0% during the 4th quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock worth $39,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Hughes Financial Services LLC purchased a new stake in Phibro Animal Health during the 3rd quarter worth about $40,000. Institutional investors and hedge funds own 99.34% of the company’s stock.

More Phibro Animal Health News

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Phibro reported better-than-expected quarterly results, with EPS of $0.76 versus $0.72 expected and revenue of $383.5 million versus $367.0 million expected. Net sales rose about 10% year over year and net income increased 15%, signaling solid operating momentum. Phibro Q3 Results
• Neutral Sentiment: The company also raised its FY2026 net sales outlook to $1.46 billion-$1.50 billion and adjusted EBITDA guidance to $247 million-$255 million, which keeps the long-term growth story intact but appears to have left some investors cautious about margins and execution. FY2026 Sales & EBITDA Guidance
• Neutral Sentiment: Management will present at the Bank of America Securities Health Care Conference next week, which could provide additional clarity on the outlook and help reset investor expectations. Conference Participation
• Negative Sentiment: CEO Jack Bendheim disclosed additional stock sales, including a sale of 4,528 shares at $48.49 and a prior sale of 7,040 shares at $55.80. Although the trades were made under a pre-arranged 10b5-1 plan, multiple insider sales in a short period can still weigh on sentiment. SEC Insider Sale Filing

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.